Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Mechanisms of transformation by the BCR/ABL oncogene.

Sattler M, Griffin JD.

Int J Hematol. 2001 Apr;73(3):278-91. Review.

PMID:
11345193
2.

Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.

Sattler M, Salgia R.

Cytokine Growth Factor Rev. 1997 Mar;8(1):63-79. Review.

PMID:
9174663
3.

Molecular mechanisms of transformation by the BCR-ABL oncogene.

Sattler M, Griffin JD.

Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10. Review.

PMID:
12783368
4.

Novel therapies for chronic myelogenous leukemia.

Jahagirdar BN, Miller JS, Shet A, Verfaillie CM.

Exp Hematol. 2001 May;29(5):543-56. Review.

PMID:
11376866
5.

Molecular biology of chronic myeloid leukemia.

Maru Y.

Int J Hematol. 2001 Apr;73(3):308-22. Review.

PMID:
11345196
6.

Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.

Warmuth M, Danhauser-Riedl S, Hallek M.

Ann Hematol. 1999 Feb;78(2):49-64. Review.

PMID:
10089019
7.

[Chronic myeloid leukemia as a model for the development and therapeutic use of tyrosine kinase inhibitors].

López-Karpovitch X.

Rev Invest Clin. 2003 Mar-Apr;55(2):191-5. Review. Spanish. No abstract available.

PMID:
12827926
8.

[Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].

Etienne G, Mahon FX.

Bull Cancer. 2001 Jul;88(7):651-8. Review. French.

9.
10.

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.

Melo JV, Deininger MW.

Hematol Oncol Clin North Am. 2004 Jun;18(3):545-68, vii-viii. Review.

PMID:
15271392
11.

[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].

Usui N.

Rinsho Byori. 2004 Feb;52(2):136-44. Review. Japanese.

PMID:
15027317
12.

[Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].

Molnár L, Losonczy H.

Orv Hetil. 2002 Oct 20;143(42):2379-84. Review. Hungarian.

PMID:
12440260
13.

Genomic instability: The cause and effect of BCR/ABL tyrosine kinase.

Skorski T.

Curr Hematol Malig Rep. 2007 May;2(2):69-74. doi: 10.1007/s11899-007-0010-6. Review.

PMID:
20425353
14.

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.

Giles FJ, Cortes JE, Kantarjian HM.

Curr Mol Med. 2005 Nov;5(7):615-23. Review.

PMID:
16305488
15.

Chronic myelogenous leukaemia--new therapeutic principles.

O'Dwyer ME, Druker BJ.

J Intern Med. 2001 Jul;250(1):3-9. Review.

16.

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

Nardi V, Azam M, Daley GQ.

Curr Opin Hematol. 2004 Jan;11(1):35-43. Review.

PMID:
14676625
17.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

18.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
19.

BCR-ABL in chronic myelogenous leukemia--how does it work?

Goldman JM, Melo JV.

Acta Haematol. 2008;119(4):212-7. doi: 10.1159/000140633. Review.

PMID:
18566539
20.
Items per page

Supplemental Content

Support Center